Intercept Pharmaceuticals’ (ICPT) Outperform Rating Reiterated at Wedbush

Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued to investors on Friday, March 9th. They presently have a $253.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $256.00. Wedbush’s price objective points to a potential upside of 302.67% from the stock’s current price. Wedbush also issued estimates for Intercept Pharmaceuticals’ FY2021 earnings at $10.38 EPS and FY2022 earnings at $21.42 EPS.

Several other analysts have also commented on ICPT. Leerink Swann reaffirmed a “hold” rating and set a $60.00 target price on shares of Intercept Pharmaceuticals in a report on Tuesday, November 28th. ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 target price on the stock. Finally, Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, December 21st. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $128.75.

How to Become a New Pot Stock Millionaire

Shares of ICPT stock traded up $2.83 during mid-day trading on Friday, reaching $62.83. The stock had a trading volume of 1,024,069 shares, compared to its average volume of 854,768. The company has a debt-to-equity ratio of 21.71, a quick ratio of 4.31 and a current ratio of 4.31. The firm has a market capitalization of $1,548.62, a PE ratio of -4.37 and a beta of -1.81. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The firm had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The firm’s revenue for the quarter was up 173.1% on a year-over-year basis. During the same period in the prior year, the company posted ($4.84) earnings per share. sell-side analysts forecast that Intercept Pharmaceuticals will post -12.6 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. DSC Advisors L.P. acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $204,000. Amalgamated Bank acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $209,000. Virtu Financial LLC acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $234,000. Oppenheimer & Co. Inc. grew its holdings in Intercept Pharmaceuticals by 145.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 2,833 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $331,000. 74.27% of the stock is currently owned by institutional investors.

WARNING: “Intercept Pharmaceuticals’ (ICPT) Outperform Rating Reiterated at Wedbush” was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://baseballnewssource.com/2018/04/03/intercept-pharmaceuticals-icpt-outperform-rating-reiterated-at-wedbush/2016092.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.